<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153035</url>
  </required_header>
  <id_info>
    <org_study_id>104603</org_study_id>
    <nct_id>NCT01153035</nct_id>
    <nct_alias>NCT01420380</nct_alias>
  </id_info>
  <brief_title>Excision Followed by Radiofrequency Ablation for Breast Cancer</brief_title>
  <acronym>ABLATE</acronym>
  <official_title>ABLATE Registry: Radiofrequency Ablation After Breast Lumpectomy (eRFA) Added To Extend Intraoperative Margins in the Treatment of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Angiodynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate, in a multi-center setting, the ability of
      radiofrequency ablation (RFA) of breast cancer lumpectomy sites to extend the &quot;final&quot;
      negative margin and consequently decrease the rates of re-operation. During the initial
      breast conservation procedure (lumpectomy), immediately following routine surgical resection
      of the tumor, radiofrequency energy (RFA) is applied to the wall (bed) of the fresh
      lumpectomy cavity, thus extending tumor free margin radially beyond the volume of the
      resected specimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the re-excision rate for close (&lt;3mm) or positive margins</measure>
    <time_frame>Post-surgery (defined as 2 weeks after surgery, to allow time for pathology to be completed)</time_frame>
    <description>How many patients must go back for re-excision of margins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease local recurrence</measure>
    <time_frame>Monitor throughout 5 year follow-up</time_frame>
    <description>The patient will be followed closely from the time of surgery through a period of 5 years in order to assess the frequency of local recurrence, defined as a new diagnosis of cancer at or near the site of primary surgery. It is our thought that the addition of RFA to the standard surgical treatment will reduce the number of local recurrences.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery followed by RFA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <description>Breast conservation surgery followed by Radiofrequency Ablation of the cavity</description>
    <arm_group_label>Surgery followed by RFA</arm_group_label>
    <other_name>AngioDynamics, Inc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a female, ≥ 50 years of age

          -  The tumor size is ≤ 3 cm (on pre-study radiologic OR clinical exam)

          -  The tumor is unicentric and unilateral

          -  The tumor is not involving the skin

          -  Pathology confirms ductal in situ (DCIS) OR infiltrating ductal carcinoma (IDC), grade
             I-III

          -  If tumor is IDC, pathology must be hormone receptor positive (ER+ and/or PR+)

          -  Patient signs current written informed consent and HIPAA forms

        Exclusion Criteria:

          -  Patient is under 50 years of age

          -  Patient is male

          -  Tumor &gt; 3 cm in diameter

          -  Bilateral malignancy

          -  Clinically positive lymph nodes

          -  Tumor involving the skin

          -  Pathology confirms invasive lobular carcinoma

          -  Breast implants

          -  Less than 2 years disease-free survival from previous breast cancer

          -  Neoadjuvant chemotherapy or chemotherapy for another breast cancer within two years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Ochoa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Scanlan</last_name>
    <phone>5015266245</phone>
    <email>bscanlan@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Scanlan</last_name>
      <email>bscanlan@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela Ochoa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Oncology (Comprehensive Breast Care of San Diego)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Breast Care of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Weber, RN, CCRP</last_name>
      <phone>303-318-2271</phone>
      <email>Nancy.Weber@sclhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Julie Barone, DO</last_name>
      <phone>303.318.3413</phone>
    </contact_backup>
    <investigator>
      <last_name>Julie Barone, DO, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stella Baccaray, RN</last_name>
    </contact>
    <investigator>
      <last_name>Marilee McGinness, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Baker, CRC</last_name>
      <phone>212-305-6679</phone>
    </contact>
    <investigator>
      <last_name>Sheldon Marc Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klimberg VS, Ochoa D, Henry-Tillman R, Hardee M, Boneti C, Adkins LL, McCarthy M, Tummel E, Lee J, Malak S, Makhoul I, Korourian S. Long-term results of phase II ablation after breast lumpectomy added to extend intraoperative margins (ABLATE l) trial. J Am Coll Surg. 2014 Apr;218(4):741-9. doi: 10.1016/j.jamcollsurg.2013.12.032. Epub 2014 Jan 11.</citation>
    <PMID>24655863</PMID>
  </reference>
  <results_reference>
    <citation>Mackey A, Feldman S, Vaz A, Durrant L, Seaton C, Klimberg VS. Radiofrequency ablation after breast lumpectomy added to extend intraoperative margins in the treatment of breast cancer (ABLATE): a single-institution experience. Ann Surg Oncol. 2012 Aug;19(8):2618-9. doi: 10.1245/s10434-012-2293-7. Epub 2012 Mar 16.</citation>
    <PMID>22422482</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson M, Korourian S, Boneti C, Adkins L, Badgwell B, Lee J, Suzanne Klimberg V. Long-term results of excision followed by radiofrequency ablation as the sole means of local therapy for breast cancer. Ann Surg Oncol. 2012 Oct;19(10):3192-8. doi: 10.1245/s10434-012-2476-2. Epub 2012 Aug 22.</citation>
    <PMID>22911363</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Conservation Therapy</keyword>
  <keyword>Lumpectomy</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

